Feb. 25, 2021: High HCV SVR among people using substances; geographic HIV care disparities among Black Americans; self-administered imiquimod vs. ASIL excision; PrEP uptake in syringe service programs.
Feb. 11, 2021: Early comorbidity development among women living with HIV; type 2 heart attack frequency; assessing European-based CVD assessment tools; long-term cognitive dysfunction and HIV/hepatitis coinfection.
Jan. 21, 2021: Dyad-level interventions in serodiscordant relationships; using social media to improve PrEP uptake; HCV prevalence among MSM; the irrelevance of doxycycline prophylaxis against mycoplasma genitalium.
No baseline genotyping. Fewer in-person medical visits and lab tests. No need for refills. Could the future of HCV treatment take place almost entirely remotely?
We spoke with Amy Killelea at NASTAD, a major national health policy advocacy organization, about the priorities she sees in January 2021 and beyond.
Oct. 22, 2020: Impact of COVID-19 shutdowns on HIV viral suppression; unsuppressed HIV viral load despite no treatment failure; point-of-care rapid testing vs. lab testing; it's not about "what," it's about "when."
For the most vulnerable populations disproportionately impacted by HCV in the U.S.—i.e., incarcerated people and people who inject drugs—treatment remains dangerously elusive, experts say.
Sept. 3, 2020: A hepatitis C microelimination program for people living with HIV; PrEP concentrations and gender-affirming hormones; a collaborative intervention to improve opioid prescribing practices; TDF and fracture risk.
With Several Curative Therapies for Hepatitis C on the Market, the Research Pipeline for Prevention Continues
The authors of an influential annual report on hepatitis C research and development talk through what's new and evolving in clinical science.
Aug. 13, 2020: HCV testing rates among people newly diagnosed with HIV; HCV treatment referrals ammong coinfected people; HIV mortality rates despite free treatment access; mysterious, plummeting CD4 test results.